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Abstract Drug resistance in malaria parasites is a serious
public health burden, and resistance to most of the antima-
larial drugs currently in use has been reported. A better
understanding of the molecular mechanisms of drug resis-
tance is urgently needed to slow or circumvent the spread
of resistance, to allow local treatments to be deployed more
eVectively to prolong the life span of the current drugs, and
to develop new drugs. Although mutations in genes deter-
mining resistance to drugs such as chloroquine and the
antifolates have been identiWed, we still do not have a full
understanding of the resistance mechanisms, and genes that
contribute to resistance to many other drugs remain to be
discovered. Genetic mapping is a powerful tool for the
identiWcation of mutations conferring drug resistance in
malaria parasites because most drug-resistant phenotypes
were selected within the past 60 years. High-throughput
methods for genotyping large numbers of single nucleotide
polymorphisms (SNPs) and microsatellites (MSs) are now
available or are being developed, and genome-wide associ-
ation studies for malaria traits will soon become a reality.
Here we discuss strategies and issues related to mapping
genes contributing to drug resistance in the human malaria
parasite Plasmodium falciparum.
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Introduction
Human malaria is caused by four Plasmodium parasites,
P. falciparum, P. vivax, P. ovale, and P. malariae, although
outbreaks of the monkey malaria, P. knowlesi, infections in
human populations have been reported (Singh et al. 2004).
Among the human parasites, P. vivax is the most wide-
spread species, and P. falciparum is the most deadly, kill-
ing 1–2 million people each year in tropical and subtropical
regions, particularly in Africa, where P. falciparum malaria
inXicts a heavy burden on human health and prosperity
(Cox et al. 2007; Snow et al. 2005).
Parasite life cycle and genome
The malaria parasite has a complex life cycle involving a
vertebrate host and mosquito vector. The life cycle of
P. falciparum consists of multiple rounds of asexual repli-
cation in the human host and both asexual (replication in
the oocyst stage) and sexual reproduction in Anopheles
mosquitoes. When a mosquito carrying sporozoites bites an
individual, some parasites enter the blood stream and rap-
idly invade hepatocytes. After replicating asexually to gen-
erate several thousand merozoites, the parasite exits the
liver and invades erythrocytes. Numerous rounds of asexual
reproduction follow, with repeated invasion of erythro-
cytes, developing from ring to trophozoite to schizont
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number of parasites circulating in the host. For as yet unde-
termined reasons, some parasites switch into sexual stages,
known as gametocytes. It takes about 12–14 days for a
committed merozoite to develop into a mature gametocyte
(Hawking et al. 1971), which circulates in the bloodstream
and is taken up by the female mosquito during a blood
meal. Within the mosquito midgut, mature male and female
gametes emerge from infected erythrocytes and fuse to
form a zygote, the brief diploid phase of the parasite life
cycle that is otherwise entirely haploid. Meiosis follows
within 3 h of fertilization (Sinden and Hartley 1985), and
the parasite develops into an ookinete that crosses the mid-
gut wall and grows into an oocyst. Mitotic division within
the oocyst produces thousands of sporozoites that break out
and travel by the hemolymph to the mosquito salivary
glands. These sporozoites are then injected into a human
host when the mosquito takes its next blood meal. The sex-
ual stages are essential for transmission, and therefore both
the transmission rate and the frequency of infections con-
taining multiple genotypes determine the eVective recombi-
nation rate that is a key consideration in genetic mapping
studies.
The parasite genome contains »23 Mb nucleotides and
is predicted to encode »5,400 genes located on 14 chromo-
somes, along with a 35-kb circular plastid genome and a 6-
kb mitochondrial genome (Gardner et al. 1993; Gardner
et al. 2002; Suplick et al. 1988; Wilson et al. 1996).
Approximately 60% of the predicted genes encode hypo-
thetical proteins, although recent re-annotation of the
genome has assigned additional putative functions to many
additional genes (PlasmoDB v5.4; http://www.plas-
modb.org/plasmo/home.jsp). Deciphering the functions of
these genes and their interactions presents a great challenge
to malaria researchers. Furthermore, applying the newly
acquired molecular knowledge to disease control, for exam-
ple, by identifying novel drug or vaccine targets, will be
another diYcult task. The availability of the genome
sequence has opened up the malaria research Weld to the
application of genome-based methodologies. Microarrays
printed with synthetic oligonucleotides, PCR products from
cDNA libraries and AVymetrix array chips have all been
used to study gene expression and regulation during para-
site development (Ben Mamoun et al. 2001; Bozdech et al.
2003; Daily et al. 2007; Hayward et al. 2000; Le Roch et al.
2002; Rathod et al. 2002; Volkman et al. 2002), to detect
copy number (CN) changes and nucleotide substitutions
(Carret et al. 2005; Jiang et al. 2008b; Kidgell et al. 2006;
Ribacke et al. 2007), and recently to study regulatory RNA
(Mourier et al. 2008). The genome sequence also provides a
resource for high-throughput proteomic analyses of various
parasite stages (Florens et al. 2002; Hall et al. 2005; Khan
et al. 2005; Lasonder et al. 2002; Sam-Yellowe et al. 2004).
These global expression and structural analyses have pro-
vided important leads to gene function and gene regulation
of the parasite, but do not identify speciWc functions for
individual genes. Decoding individual gene function will
require multiple, cross-discipline approaches, including
methods of biochemistry, cell biology, physiology, genet-
ics, etc. Genetic transformation is one of the useful tech-
niques playing an increasing important role in studying
gene function (Crabb and Cowman 1996; Crabb et al. 1997;
Maier et al. 2008; van Dijk et al. 1995; Wu et al. 1995; Wu
and Wellems 1996), especially for genes that are active in
the sexual stages (Furuya et al. 2005; Lobo et al. 1999;
Menard et al. 1997; van Dijk et al. 2001). However,
because malaria parasites are haploid, lethal disruptions or
Wtness costs aVecting growth limit the ability to generate
knockouts for many genes expressed in the asexual stages.
Drug resistance in the P. falciparum malaria parasite
Chloroquine (CQ) resistance (CQR)
The majority of studies on drug resistance have focused on
those of P. falciparum, although CQR in P. vivax has
received increasing attention (Baird et al. 2007; RatcliV
et al. 2007; White 1998). CQR in P. falciparum was
reported in two foci on the Thai–Cambodia border and in
Colombia in the late 1950s and early 1960s, respectively,
and has since spread to all the major malaria endemic
regions, including Africa and South America (Fig. 1a)
(Chen et al. 2003; Payne 1987; Vieira et al. 2001; Wootton
et al. 2002). Mutations in a putative transporter, PfCRT
(P. falciparum chloroquine resistance transporter), deter-
mine CQR, in particular a substitution at amino acid posi-
tion 76 (Cooper et al. 2002; Djimde et al. 2001; Fidock
et al. 2000; Sidhu et al. 2002). Mutations and CN changes
in another gene (pfmdr1) that encodes a homolog of the
human multi-drug resistance p-glycoprotein (PfPgh1) were
also associated with CQR or pfcrt mutations (Djimde et al.
2001; Duraisingh et al. 2000; Foote et al. 1990; Foote et al.
1989; Mu et al. 2003), but the contribution of pfmdr1 in
modulating CQR is still unknown (Hayton and Su 2004).
Additionally, parasite isolates that carry the same pfcrt and
pfmdr1 alleles, but have diVerent CQ phenotypes as mea-
sured by IC50, suggest that additional genes modulate the
parasite response to CQ (Ferdig et al. 2004; Mu et al.
2003). These additional genes may encode various trans-
porters, for example, other ABC transporters that can mod-
ulate food vacuole pH (Cooper et al. 2005; Jiang et al.
2006; Zhang et al. 2002) or could include molecules
involved in GSH-mediated degradation of ferriprotopor-
phyrin (FP) and/or GSH drug adduct transport (Borst et al.
2000; Ginsburg and Golenser 2003).123
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Resistance to SP, a combination of pyrimethamine (PYR)
and sulfadoxine (SDX), was also Wrst reported in Thailand
(Chongsuphajaisiddhi et al. 1979). Both drugs are antifo-
lates and exhibit a high degree of synergy when adminis-
tered together (Chulay et al. 1984). PYR is structurally
similar to dihydrofolate, and SDX is an analog of p-amino-
benzoic acid (PABA); therefore, PYR and SDX are com-
petitive inhibitors of dihydrofolate reductase (DHFR) and
dihydropteroate synthethase (DHPS), respectively. These
are key enzymes in the folate pathway, and mutations in
dhfr and dhps have been demonstrated to confer resistance
to PYR and SDX (Cowman et al. 1988; Peterson et al.
1990; Peterson et al. 1988; Reeder et al. 1996; Siriwaraporn
1998; Triglia et al. 1997); however, one major diVerence
between PYR resistance and CQR is the number of inde-
pendent mutation events, known as founder mutations.
There have been only a limited number of founder muta-
tions for CQR (Wve described to date) (Fig. 1a) (Chen et al.
2003; Wootton et al. 2002). In contrast, low levels of PYR
resistance can occur quite frequently, because the resistance
is conferred by a single point mutation in the dhfr gene.
Higher levels of PYR resistance, however, require multiple
additional mutations in dhfr that also appear to have limited
origins and diVerent scales of selective sweeps (Fig. 1b)
Fig. 1 The spread of CQR- and high level PYR-resistant P. falcipa-
rum can be traced to only a few independent origins. a Mutations in
pfcrt conferring CQR originated and spread from at least Wve indepen-
dent foci, including a single origin of all CQR alleles in Southeast Asia
and Africa, two independent origins in South America, one in Papua
New Guinea, and at least one origin in Melanesia (Chen et al. 2003;
Wootton et al. 2002). Areas colored in red indicate the presence of
CQR P. falciparum, while black circles indicate the spread of CQR
parasites from the origins. b Triple or quadruple mutant pfdhfr alleles
conferring high level PYR resistance can also be traced to a few ori-
gins. All alleles found in Southeast Asia and the majority of African
parasites share a common ancestor, with at least one other independent
origin in South America, one additional African origin in Kenya and an
independent origin in Melanesia (Cortese et al. 2002; Maiga et al.
2007; McCollum et al. 2007; McCollum et al. 2006; Mita et al. 2007;
Nair et al. 2003; Roper et al. 2003; Roper et al. 2004). The labeling of
origins represents approximate reported locations, not the actual ori-
gins or the scale of a region that a particular allele covers. More inde-
pendent pfdhfr triple or quadruple mutants are expected when more
samples from diVerent endemic regions are typed. Areas shaded in yel-
low are conWrmed to harbor both CQR and high-level PYR-resistant
parasites, while areas colored in red indicate the presence of CQR P.
falciparum, where high-level PYR resistance is either absent or un-
known. CQ chloroquine, PYR pyrimethamine, pfcrt P. falciparum
chloroquine resistance transporter, dhfr dihydrofolate reductase. This
Wgure was modiWed from Wellems (2004) and (Guerra et al. (2008)123
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2007; McCollum et al. 2006; Mita et al. 2007; Nair et al.
2003; Roper et al. 2003; Roper et al. 2004). In addition,
mutations and/or gene expression changes in other genes in
the folate metabolism pathway may also contribute to SP
resistance (Kidgell et al. 2006; Volkman et al. 2007; Wang
et al. 1997).
MeXoquine (MQ) resistance (MQR)
MQ had been extensively used only in Southeast Asia, and
parasites resistant to MQ were reported after only a few
years following the introduction of the drug (Boudreau
et al. 1982; Nosten et al. 1991). Currently, MQ is ineVec-
tive on the Thai–Cambodia border and has been removed
from the treatment plans of many countries in the region.
AmpliWcation of pfmdr1 (increased copy number, CN) has
been associated with increased MQ IC50 (Cowman et al.
1994; Peel et al. 1994; Price et al. 1999; Price et al. 2004;
Sidhu et al. 2006; Wilson et al. 1989); and disruption of one
of two copies of pfmdr1 in the FCB parasite led to a
decrease in IC50 to MQ, ART, lumefantrine, haloafntrine
(HAL), and QN (Sidhu et al. 2006). However, several lines
of evidence question the role of ampliWed pfmdr1 in MQR:
(1) MQ selection of P. falciparum parasites does not
always lead to increased pfmdr1 CN (Lim et al. 1996); (2)
not all Weld studies showed an association of MQR with
increased pfmdr1 CN (Chaiyaroj et al. 1999); and (3)
because increased MQ IC50 levels appear to correlate with
increased IC50 in parasite response to QN and HAL, higher
pfmdr1 CN could be due to selection of QN and/or other
drugs (Cowman et al. 1994). Support for the cross-resistant
theory came from Africa, where parasites resistant to MQ
were detected in areas where QN has been widely used, but
not MQ (Brasseur et al. 1991; Brasseur et al. 1992; Lobel
et al. 1998). Therefore, because pfmdr1 appears to play a
role in parasite responses to many drugs, the association of
pfmdr1 CN and increased MQ IC50 could simply reXect the
combinational results of extensive selection of multiple
drugs on P. falciparum parasites. The association of higher
levels of MQ IC50 to higher pfmdr1 CN could also reXect
low-level compensatory responses to MQ selection. Also,
ampliWcation of pfmdr1 may be a broad parasite compensa-
tory response to physiologic changes in the food vacuole
due to mutations in pfcrt and other genes (Jiang et al.
2008a).
Increased pfmdr1 CN predicts potentially higher levels
of mRNA transcript and its protein product, PfPgh1; how-
ever, few studies show good correlation of pfmdr1 CN with
its mRNA or protein expression levels. Higher levels of
mRNA and PfPgh1 appeared to correlate with higher IC50
levels in laboratory selected parasites (Cowman et al. 1994;
Jiang et al. 2008a) and genetic cross progeny (Rohrbach
et al. 2006) but not in other studies (Lim et al. 1996). Firm
correlation of pfmdr1 CN and mRNA or protein levels will
require further investigation. Considering all the factors
that can inXuence pfmdr1 CN and the diYculties to date in
accurately measuring PfPgh1 levels, the precise role of
pfmdr1 in MQR remains an open question.
Quinine resistance (QNR)
QN has been used to treat malaria for hundreds of years and
is still eVective in treating P. falciparum and other para-
sites, particularly when combined with other drugs (Ejaz
et al. 2007; Pukrittayakamee et al. 2000), although its
eYcacy is declining in some endemic regions (Pukritta-
yakamee et al. 2000; Pukrittayakamee et al. 1994; Zalis
et al. 1998). The molecular basis of QNR, as deWned by an
increase of in vitro IC50, remains uncertain, although vari-
ous molecules have been reported to play a role in parasite
response to QN. pfcrt, a gene encoding a putative Na+/H+
exchanger (PfNHE), pfmdr1, and a locus on chromosome 9
have all been associated with higher levels of IC50 in prog-
eny of a genetic cross (Ferdig et al. 2004; Wellems et al.
1990). The role of pfmdr1 in QNR was consistent with the
report that the N1042D substitution in PfPgh1 contributed
to QNR (Sidhu et al. 2005), and the involvement of PfNHE
in QNR was also supported by a recent observation that ele-
vated PfNHE activities were found in parasites with high
levels of QN IC50 (Bennett et al. 2007). Both PfPgh1 and
PfNHE may play a role in regulating cytosolic and/or vacu-
olar pH, leading to changes in drug accumulation (Bennett
et al. 2007; Rohrbach et al. 2006). Other unknown trans-
porters, particularly ABC transporters, may also contribute
to QNR, because the P. falciparum parasite response to QN
is probably a multi-gene trait (Ferdig et al. 2004; Mu et al.
2003), and the requirement of multiple loci for QNR may
explain why QN is still eVective in treating malaria para-
sites after »350 years of use. Again, the molecular mecha-
nism and mutations underlying QNR require further
investigation.
Resistance to artemisinin (ART)?
ART, also called Qinghaosu, was Wrst isolated from a Chi-
nese herb Huanghuahao (Artemisia annua L.) in 1972, and
its structure and pharmacologic properties were Wrst char-
acterized and published by Chinese scientists in 1978
(Qinghaosu Research Group 1978; Zhang 2006). DeWnitive
antimalarial activities of ART were published in an English
Chinese medical journal in 1979 (Qinghansu Antimalarial
Co-ordinating Group 1979). ART and its derivatives are
safe and eVective against all asexual stages and gameto-
cytes, particularly when administered in combination with
other drugs (Nosten and White 2007). Resistance to ART123
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decreased parasite susceptibility to the drug has been
reported (Laufer et al. 2007; Lim et al. 2005; Wongsrichan-
alai and Meshnick 2008). Positive correlations in parasite
responses (in vitro IC50) to ART, MQ, HAL, lumefantrine
and possibly QN and partial negative correlation of ART to
CQ have been reported (Basco and Le Bras 1992, 1993;
Chaijaroenkul et al. 2005; Cowman et al. 1994; Pradines
et al. 2006; Price et al. 2004). Selection of P. falciparum
parasites with MQ usually leads to increased MQ IC50 but
increased sensitivity to CQ and vice versa, which can be
again correlated with increased pfmdr1 CN (Cowman et al.
1994). Therefore, the low-level increase in ART IC50 in
some parasites could be cross-resistance to MQ, QN, or
might have been selected by other drugs and not due to true
ART pressure. These cross-resistance patterns suggest sim-
ilar pathways or genes that are involved in metabolism and/
or parasite uptake of these drugs and raises an important
issue regarding the use of drug combinations containing
ART and its derivatives with either MQ or HAL. Consider-
ing the extensive MQR in Southeast Asia and negative cor-
relation of ART and CQ, use of MQ and ART
combinations may not be much better than a combination
of CQ and ART, particularly in West Africa where CQ is
still quite eVective.
Another candidate gene that has been associated with
parasite response to ART is PfATP6 (Jambou et al. 2005).
ART was shown to inhibit the ATPase activity in an oocyte
expression system (Eckstein-Ludwig et al. 2003); however,
the association of mutations in PfATP6 with ART resis-
tance requires further conWrmation, particularly as clini-
cians are uncertain whether true ART-resistant parasites
have even arisen yet. For more information on other anti-
malarial drugs and resistances, readers are referred to other
excellent reviews (Baird 2005; Le Bras and Durand 2003;
White 1999).
The putative interactions of diVerent proteins in the food
vacuole are summarized in Fig. 2.
Drug assays and phenotype measurement
Genome-wide association studies now oVer an opportu-
nity to detect genome variation underlying parasite drug
responses. While much attention has focused on the
development of high-throughput techniques to detect
genetic variation (genotyping), the most critical issue is
the accurate measurement of parasite drug response (phe-
notyping). Over the years, many methods have been
developed to evaluate P. falciparum parasite responses to
antimalarial drugs and to monitor therapeutic eYcacy. For
drug resistance surveys, both in vivo and in vitro methods
have been used. In vivo surveys analyze parasite clear-
ance time using established treatment regimens, typically
involving the microscopic examination of a patient blood
smear 7–28 days after drug administration following
World Health Organization guidelines (WHO 2000). For
a more quantitative measure, many in vitro drug assays
have also been developed. These assays are based on mea-
suring parasite growth or growth inhibition under various
drug concentrations, and proliferation is quantiWed by
either counting parasitemia microscopically (Rieckmann
et al. 1978), measuring [3H] hypoxanthine incorporation
(Desjardins et al. 1979), parasite lactate dehydrogenase
activity (Makler et al. 1993), or signals from antibodies
against histidine-rich protein II (HRPII) (Noedl et al.
2005, 2002), and more recently by quantifying the amount
of parasite DNA with SYBR green or DAPI dyes (Bennett
Fig. 2 Potential molecular interactions in P. falciparum responses to
multiple antimalarial drugs. A White pathway: CQ pressure leads to
mutations in PfCRT that can aVect CQ transport and/or FV pH. To
compensate mutations in pfcrt, other changes such as CN changes or
nucleotide substitutions in pfmdr1 and other molecules may be re-
quired. The reduction in pfmdr1 CN under CQ selection suggests that
PfPgh1 may act as a transporter, transporting CQ in the opposite direc-
tion of that of PfCRT. B Green pathway: QN resistance requires chang-
es in multiple genes, which could explain the slow emergence of QNR
and how QN use might have contributed to pfmdr1 CN increase in Af-
rica. C Black pathway: MQ and HAL could act either on pfmdr1 and/
or on other unknown genes, leading to increases in pfmdr1 CN. Ampli-
Wcation of pfmdr1 may not be the major mechanism mediating MQ
resistance, but similar to CQR, CN changes may represent a compen-
satory response to restore parasite Wtness. D Blue pathway: involve-
ment of pfmdr1 in ART resistance is likely a background low-level
association that could be due to selection by other drugs. Clinical ART
treatment failures due to ART resistance have yet to be conWrmed and
therefore the role of PfATP6 in resistance remains questionable. FV
food vacuole, RBC red blood cell, CN copy number, CQ chloroquine,
QN quinine, MQ meXoquine, HAL halofantrine, and ART artemisinin.
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These assays have been widely used to survey parasite
responses to drugs in laboratories and at Weld sites. Test-
ing drug responses at Weld sites is particularly challenging
because parasites are often tested directly following isola-
tion from patient blood samples or after a very brief time
in tissue culture. There are many factors that can inXuence
drug test results that are assessed either in vivo or in vitro
using blood samples collected directly from patients. (1)
Parasites usually require a period of adaptation before
they can grow in culture, and many parasites die because
of problems surviving in vitro culture conditions, regard-
less of drug sensitivity; (2) patients may have taken medi-
cation before being sampled, possibly leading to false
negative results; (3) patient blood usually contains diVer-
ent numbers of parasites, and drug assays are sensitive to
variation in parasitemia; (4) patient blood is usually sam-
pled just once before antimalarial drug treatment, prevent-
ing repeated tests at diVerent times; and (5) mixed
infections of diVerent genotypes are highly prevalent in
malaria endemic areas, particularly in Africa and South-
east Asia (Bendixen et al. 2001; Kobbe et al. 2006).
Mixed infection of parasites resistant and sensitive to a
drug may produce IC50 measurements that do not reXect
the true IC50 values of the parasites (Liu et al. 2008).
Therefore, while in vitro drug tests using patient blood
samples may be a good method for therapeutic eYcacy
surveys, they may not provide an accurate measurement
of individual parasite drug response, which is a critical
requirement for mapping loci aVecting drug resistance,
particularly those controlled by multiple quantitative trait
loci (QTL). Therefore, adapting Weld isolates to in vitro
culture and cloning individual genotypes before drug test-
ing will be necessary for accurate and reproducible mea-
surements of parasite drug response to ensure that
genome-wide association studies will be informative. It is
diYcult, however, to correlate in vitro IC50 measurements
with a drug concentration that is predictive of clinical
resistance. The IC50 value that corresponds to clinical
drug failure depends on many factors. The threshold IC50
for CQ and PYR are well characterized, but for many
other drugs, IC50 values predictive of clinical resistance
are unknown. For CQR, the diVerence in IC50 between
Dd2 (404 nM), a typical CQR parasite, and HB3 (34 nM),
CQS parasite, is approximately 10-fold (Mu et al. 2003).
Each drug requires studies comparing in vitro IC50 values
of parasites from clinical treatment failures and parasites
from patients who are successfully cured in order to
deWne in vitro drug resistance. As discussed above, many
factors can inXuence both clinical treatment outcome and
in vitro drug test results and these factors will have to be
carefully addressed when conducting this type of correla-
tion study.
Approaches for mapping malaria phenotypes
Linkage mapping
An important approach to study gene function is genetic
mapping. In principle, phenotypic diVerences can be linked
to genetic variations, providing functional clues of the
linked genes. This approach is based on detecting associa-
tion or linkage of certain genetic variations with a speciWc
phenotype (Su and Wootton 2004). Linkage mapping using
progeny from genetic crosses has been proven to be very
powerful, leading to the identiWcation of loci linked to drug
resistance, immunity, and other traits (Furuya et al. 2005;
Hayton et al. 2008; Martinelli et al. 2005; Peterson et al.
1988; Su et al. 1997; Vaidya et al. 1995; Wang et al. 1997;
Wellems et al. 1990). A genetic cross is performed by feed-
ing mosquitoes infectious gametocytes from two parents
with diVerent phenotypes. For P. falciparum crosses, fol-
lowing fertilization and development in the mosquito mid-
gut, sporozoites are injected into the blood stream of a
chimpanzee by mosquito bite. After completing the liver
stage, the recombinant progeny infect erythrocytes and are
adapted to in vitro tissue culture. Individual clones are sub-
sequently obtained after limiting dilution of blood samples
containing the erythrocytic stages. One example of using
genetic mapping to successfully identify genes associated
with a speciWc phenotype is the mapping and identiWcation
of pfcrt, the gene that plays a key role in CQ resistance in
P. falciparum (Fidock et al. 2000; Su et al. 1997; Wellems
et al. 1990; Wellems et al. 1991). The advantage of map-
ping using progeny from genetic crosses is that the genetic
backgrounds in the progeny are derived from the two par-
ents, eliminating the noise observed in studies using Weld
isolates with diverse genetic backgrounds.
Candidate gene association
Despite the power of classical genetics, the process of gen-
erating a cross is labor intensive, expensive, ethically chal-
lenging (use of non-human primates should be minimized),
and requires special facilities for raising mosquitoes and
primates that are available to only a few institutions. There-
fore, another approach, population-based allelic associa-
tion, is extremely attractive to malaria researchers, as the
continued advances in techniques to detect genetic varia-
tion can be readily performed in individual laboratories. To
date, most association studies in malaria parasites have
been analyzed using the ‘candidate gene’ approach. The
search for an association of mutations in pfmdr1 with para-
site responses to CQ is one example of the candidate gene
method (Djimde et al. 2001; Duraisingh et al. 2000; Hayton
and Su 2004; Su and Wootton 2004; Valderramos and
Fidock 2006). This approach, however, requires some123
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approach of candidate gene association is somewhat
between single-gene association and genome-wide associa-
tion. A group of genes within a pathway or having similar
functions can be tested for association to a phenotype based
on the known functions of these genes. One example for
P. falciparum was the association of multiple transporters
with parasite responses to CQ and QN (Mu et al. 2003),
although the results from this study have yet to be con-
Wrmed. This study was based on the observation that vari-
ous transporters, particularly the ABC transporters, have
been shown to contribute to drug resistances in many
organisms (Dean and Annilo 2005).
Genome-wide association
Genome-wide characterization of genetic variation in
P. falciparum now provides the opportunity to perform
genome-wide association studies (JeVares et al. 2007; Mu
et al. 2007; Volkman et al. 2007). These studies rely on the
presence of linkage disequilibrium (LD) in the parasite
populations being tested. LD refers to the nonrandom asso-
ciation of alleles, which can be aVected by diVerent factors
such as the physical distance between the loci and the
genetic markers used to genotype the parasite DNA, recom-
bination rate, age of the mutations, population structures,
and other factors. Sexual recombination is an obligatory
part of the lifecycle and malaria parasites produce both
males and females. Therefore, self-fertilization can readily
occur between gametes with identical genotypes, especially
in areas with low transmission rates where single-clone
infections prevail, or in homogeneous parasite populations
that, for example, can result from a recent outbreak. LD can
occur in natural populations where self-fertilization pre-
dominates to such an extent that the rate of recombination
is not high enough to randomize genomes or break up
clonal associations. This situation is relevant to malaria
trait mapping, as outbreaks can occur in areas that were
previously malaria free when travelers infected with
malaria parasites return from malaria-endemic regions. A
parasite population emerging from a recent selective drug
sweep will also have limited diversity, leading to a rela-
tively clonal population or high degree of LD. LD can also
be the result of admixture of two or more subpopulations
that have diVerent allele frequencies. This situation can be
created artiWcially when DNA samples for an association
study are collected from parasites with diVerent evolution-
ary histories or from diVerent geographic origins. For
example, P. falciparum and P. vivax parasites clustered
largely according to their continental origins (Anderson and
Day 2000; Joy et al. 2006; Mu et al. 2005; Volkman et al.
2007; Wootton et al. 2002), and mixing samples from
diVerent continents will likely produce artiWcial LD or false
association if potential population structures are not prop-
erly evaluated. Care should also be taken for samples from
diVerent countries within a continent, or even within a
country, with the exception of Africa, where high transmis-
sion rates and recombination rates may lead to low levels of
structured populations (Mu et al. 2005; Volkman et al.
2007). High recombination rates, however, can also quickly
reduce LD, making association studies diYcult. Therefore,
the population structure of parasites in the area to be sam-
pled should be assessed before starting a genome-wide
association study to reduce the chance of obtaining false
LD and can be analyzed using various methods (Long
1991; Pritchard et al. 2000).
The chances of detecting LD between a genetic marker
and an aVected gene decreases with the increased distance
between the aVected gene and the marker, as well as with
the number of generations since the origin of the mutation
(Collins and Morton 1998; Kruglyak 1999). A malaria par-
asite can complete its life cycle within 2 months if optimal
transmission conditions exist. Because of this short genera-
tion time and high recombination rate, a large number of
genetic markers may be required to map genes in organisms
such as malaria parasites. The recombination rate was esti-
mated to be »15 kb per cM in a genetic cross and among
some Weld populations (Mu et al. 2005; Su et al. 1999;
Volkman et al. 2007). The requirement for high marker
coverage is particularly true for mapping genes with
ancient mutations or mutations with unknown history, such
as genes that contribute to virulence or parasite develop-
ment. Additionally, a disease phenotype such as virulence
is likely to be the result of host and parasite interactions,
and mapping these disease-related phenotypes will require
a consideration of variation in the host genome as well as
variation in the parasite genome. This will likely become
another important topic in malaria research, as high-density
human genotyping arrays containing >500,000 features are
now available for genome-wide association studies in
humans (Gunderson et al. 2006). These arrays can be used
to scan the human genome for loci inXuencing the pathol-
ogy and outcome of malaria infection.
Most recent genome-wide association studies were con-
ducted using a multi-stage approach (Hirschhorn and Daly
2005; Lowe et al. 2004). For the initial scan, a modest
threshold is used to identify potential candidates. All the
positive candidates are then tested in a second independent
population with sample size similar to that of the initial
population. At the second stage, only a small fraction of the
initial markers, in particular those that were positive in the
initial scan are tested. Indeed, the two-populations concept
has already been applied to candidate gene association in
P. falciparum (Anderson et al. 2005).
To date, no well-designed genome-wide association
studies for malaria traits has yet been reported. One proof-123
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and showed that a large segment of chromosome 7 contain-
ing pfcrt could be detected using the MS markers (Wootton
et al. 2002). With the development of high-throughput
genotyping technologies, many genome-wide association
studies for genes aVecting drug resistance and other traits
can be expected soon.
Methods of high-throughput genotyping
Microsatellites
MSs and single nucleotide polymorphisms (SNPs) are the
two most commonly used genetic markers for genotyping
and for genetic mapping studies in malaria parasites. Com-
pared with SNPs, MSs are usually highly polymorphic with
multiple alleles in the parasite populations (Su et al. 1999;
Su and Wellems 1996). The higher diversity of MSs can be
advantageous for mapping genes that have undergone a
recent drug selective sweep (Anderson 2004; Su et al.
2007; Wootton et al. 2002); however, the high mutation
rates in MS markers may lead to homoplasy or disruption
of LD if the parasite populations are separated for a long
period of time (Anderson et al. 2000). Although a large
number of MSs can be typed relatively easily using an auto-
matic DNA sequencer and multiplex reactions, the through-
put of MS typing is quite limited compared with SNP
typing methods that have recently been developed (Gunder-
son et al. 2005; Hagiwara et al. 2007; Hardenbol et al.
2005; Kennedy et al. 2003; Lindblad-Toh et al. 2000; Stee-
mers and Gunderson 2007). Indeed, SNP is replacing MS
for large-scale genotyping; however, MS can still be very
useful for small-scale typing projects, for example, to ver-
ify a parasite identity or to identify mixed infections. Poly-
morphic MSs are extremely abundant (one in less than a
kb) in the P. falciparum (Su and Wellems 1996) but not in
the P. vivax (Feng et al. 2003) genome. In principle, an
extremely high-density MS genetic map can be developed
for genetic mapping for P. falciparum traits if an economic
and high-throughput typing method can be developed (Li
et al. 2007).
Single nucleotide polymorphisms
With the development of new technologies and recent col-
lections of large number of SNPs (JeVares et al. 2007; Mu
et al. 2007; Volkman et al. 2007), it is becoming more and
more practical and economical to conduct genome-wide
association studies that require no prior assumptions or
knowledge of gene function or mutations underlying a phe-
notypic change (Anderson 2004). These high-throughput
SNP typing methods (Gunderson et al. 2005; Hagiwara
et al. 2007; Hardenbol et al. 2005; Kennedy et al. 2003;
Lindblad-Toh et al. 2000; Steemers and Gunderson 2007)
have recently led to the successful identiWcation of several
candidate genes (loci) associated with various human dis-
eases (Buch et al. 2007; Hakonarson et al. 2007; Saxena
et al. 2007; Scott et al. 2007; Sladek et al. 2007; Tomlinson
et al. 2007; Winkelmann et al. 2007; Zanke et al. 2007).
Various methods have been or are being developed for
typing SNP in malaria parasites such as pyrosequencing
(Cheesman et al. 2007; Takala et al. 2006) and real-time
PCR/MCA assay (Mens et al. 2008). However, eVective
and user-friendly high-throughput SNP typing methods for
malaria parasites are still under development, but the prin-
ciples or methods for typing human SNPs can readily be
employed for typing malaria parasite genomes. Currently,
the most promising methods for typing malaria parasites
are microarray-based hybridizations. Indeed, a relatively
high-density array has been successfully used to detect sin-
gle feature polymorphisms (Kidgell et al. 2006). Another
AVymetrix array containing »2.32 million P. falciparum
probes (25-mer) designed at the Sanger Center, UK, is
commercially available and can be explored for typing the
P. falciparum genome (PFSANGER array) (Jiang et al.
2008b; Mourier et al. 2008). A third P. falciparum speciWc
array using the molecular inversion probe (MIP) (Absalan
and Ronaghi 2007; Hardenbol et al. 2003) method has also
been developed for typing parasite SNPs (Mu et al.,
unpublished). This array contains approximately 3,500
SNPs from the P. falciparum genome and can be useful for
mapping mutations of recent occurrence, such as those
conferring drug resistance. The advantages of the MIP
array include a lower cost per slide/chip, because they uti-
lize standard oligonucleotide design (»$200 vs. »$500 for
tiling array) and are able to detect a relatively small
amount of DNA (»100 ng) due to the speciWc ampliWca-
tion of the DNA fragments to be tested. The disadvantage
of the MIP array is the limited number of SNPs that can be
printed in an array (200,000 maximum currently) due to
limits in the techniques used. All of these arrays will play
an important role in mapping malaria phenotypes. For the
P. falciparum genome, one potential problem is that the
high AT content and abundance of repeat elements in the
genome may prevent designing probes to cover the major-
ity of the noncoding regions properly. Therefore, printing
arrays with much higher numbers of probes may not sig-
niWcantly improve the coverage of the P. falciparum
genome. Other genotyping arrays such as AVymetrix 3 and
75 K arrays (S. Volkman, D. Wirth et al., Harvard Univer-
sity), NimbleGen 60-mer oligo array (M. Ferdig, Notre
Dame University), and another AVymetrix tiling array
with »5 million probes (E. Winzeler, Scripps Institute)
have been described at various meetings, but have not yet
been published.123
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Another promising approach for the large-scale genotyping
of parasites is high-throughput parallel genome sequencing,
as new technologies have dramatically reduced the time
and expense of sequencing (Bennett et al. 2005). Obtaining
the DNA sequence is more informative than typing known
SNPs, and if the cost of sequencing continues to decrease to
a point comparable to the cost of array-based typing, mas-
sively parallel sequencing using the Solexa Sequence Ana-
lyzer (Illumina, Inc.), the Genome Sequencer FLX System
(454, Inc.) or the SOLiD system (Applied System, Foster
City, CA) may become the Wrst choice for large-scale geno-
typing. For example, this ‘next-generation’ sequencing
technology has reduced the cost of sequencing the human
genome, which originally cost »$2.7 billion and took
13 years to complete, to <$1.5 million for a full human
genome to be decoded in just 4 months (Wadman 2008).
Ultimately, the goal is to reduce this to $1,000 or less (Col-
lins et al. 2003). However, because these methods only
sequence short stretches of DNA (»35–250 bp), they cur-
rently depend on the availability of a reference genome. So
for the immediate future, it will likely only be used for
genome resequencing. This makes the method highly appli-
cable to studying P. falciparum genetic variation, but even
so, the high AT content and repetitive nature of the genome
can present problems in sequence alignment that may lead
to false SNP calls. In addition, handling the large amount of
sequence data generated can be a diYcult task for the aver-
age laboratory without high-capacity computing power.
Factors that may aVect mapping studies in malaria 
parasites
Before a study can be properly performed, some practical
issues such as the number and types of genetic markers,
sample size, amount of DNA required, and statistical meth-
ods for analysis have to be considered. Other factors that
can inXuence mapping outcomes and sample size calcula-
tions include the strength of LD between the trait-inXuenc-
ing allele and neighboring marker alleles in the parasite
populations to be studied, the frequency of the trait-inXu-
encing allele, the eVect or penetrance of the trait-inXuenc-
ing allele on the phenotype, parasite population admixture,
sample selection bias, and frequencies of recombination
between neighboring marker loci (Schork 2002; Wang
et al. 2005). MisclassiWcation of phenotypes (or inaccuracy
in drug tests) is another critical component that can lead to
false associations but often does not receive adequate atten-
tion. Calculations of statistical power and sample size are
also often problematic because many of these parameters
are unknown or diYcult to predict. Therefore, it is diYcult
to estimate the sample size and marker coverage required
for an association study without a good understanding of
the factors that can inXuence the outcome of the study. It is
possible, however, to make some estimates of these param-
eters based on what we know about the transmission inten-
sity, recombination rate, and the history and incidence of
drug resistance. To address some of the frequently asked
questions, here we discuss a few important and unique
issues associated with studies of human malaria parasites.
Blood samples and DNA preparation
One advantage of performing genetic association studies in
malaria parasites is that the haploid genome requires no
phase determination; however, there are many diYculties
associated with working with malaria parasites. First,
patient blood samples usually have relatively low parasite-
mia (<1%), making it diYcult to obtain a large quantity of
parasite DNA for genotyping. Second, patients are often
infected with parasites of diVerent genotypes that require
isolation of individual clones. These issues not only create
problems for drug assays, but also make genotyping of
DNA extracted from blood samples diYcult. In most Weld
studies, a small amount of blood (1–2 drops) is typically
spotted on a Wlter for easy storage and transportation. DNA
extracted from the Wlter paper may be suYcient for PCR
ampliWcation (often requiring nested PCR) but generally
are not suYcient for high-throughput methods such as array
hybridization or multiple rounds of MS typing. Proper
genotyping and drug assay often requires adaptation of the
parasites into in vitro culture and, if necessary, cloning of
individual parasites. This process can take weeks or months
before an appropriate amount of DNA from a cloned para-
site can be obtained for analysis. To streamline the process
and to avoid laborious parasite cloning, DNA from patient
blood can be genotyped directly using a set of highly poly-
morphic MS markers (6–10 markers); only the samples
containing a single infection are selected for further analy-
sis and adapted to in vitro culture. Genome-wide ampliWca-
tion of DNA isolated from Weld samples using commercial
kits such as REPLI-g® Whole Genome AmpliWcation
(QIAGEN) or GenomiPhi DNA AmpliWcation kit (Wang
et al. 2008) can increase the amount of DNA in a samples
300–400 times. However, this approach will also not solve
the problem of mixed infections. In addition, an individual
white blood cell contains »100-fold more DNA than a par-
asite; so even though DNA can be ampliWed, the majority
of the DNA ampliWed will be host derived if the human
DNA is not removed before ampliWcation. To obtain a suY-
cient amount of DNA for large-scale genotyping, it is nec-
essary to extract DNA from blood samples after removing
white blood cells or to obtain DNA from culture-adapted
parasites and various methods and commercial products123
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tion (Carlton et al. 2001).
Drug selective sweep and sampling sites
Because almost all the parasites circulating in Southeast
Asia (Thailand, for example) are resistant to CQ (i.e., the
resistant alleles are Wxed), we should be able to readily
detect a reduction in allelic diversity in the chromosome
region surrounding the pfcrt gene among CQR parasites
(Wootton et al. 2002), although the region of reduced diver-
sity may be small after »60 years of transmission and
recombination. CQR parasites appeared on the Thai–Cam-
bodia border in the late 1950s, spread to east Africa in the
late 1970s, and reached West Africa in the 1990s (Fig. 1a)
(Payne 1987; Wootton et al. 2002); however, it can be
expected that higher levels of LD surrounding the pfcrt
gene can be found in West Africa because despite higher
transmission rates, there has been a shorter time for recom-
bination to break down linkage and to reduce LD. Indeed, a
chromosome 7 segment surrounding pfcrt that contained
more than 200 kb (»1% of the genome) exhibited LD in
CQR parasites collected from Southeast Asia (some were
collected more than 20 years ago) and Africa during 1980–
2000 (Wootton et al. 2002). In this case, the region contain-
ing pfcrt was easily detected using 342 genome-wide MS
markers. The results also showed the presence of a large
CQ selective sweep from Southeast Asia to Africa (Woot-
ton et al. 2002) and that signatures of a drug selective
sweep can be used to detect loci conferring drug resistance
(Anderson 2004; Nair et al. 2003; Roper et al. 2003; Roper
et al. 2004). Whole genome long-range haplotype tests that
have been widely used to detect positive selection in human
genome can also be applied to search for signatures of
selection in the parasite genome (Sabeti et al. 2007; Volk-
man et al. 2007; Zhang et al. 2006). However, the selection
signature may not be obvious if the beneWcial alleles have
multiple origins (Nair et al. 2007) or multiple genes in the
genome are subject to the same selection force.
The consideration of LD and history of drug resistance
highlights the important issue of sampling location when
designing an association study. It is preferable to sample par-
asites from locations with frequencies of resistant parasites of
between 20 and 50% so the proportions of both resistant and
sensitive parasites are approximately equal, therefore giving
a good chance of having detectable LD. A resistant allele fre-
quency of 20–50% will greatly reduce the sample size
required to detect associations (Wang et al. 2005).
Number of genetic markers available to use in a study
Because of diYculties in obtaining high-quality DNA sam-
ples from cloned parasites and the laborious processes of
generating accurate phenotype data in drug assays, use of as
small a sample size as possible will save time and money.
Considering that most drug resistances are recent founder
mutations with relatively high variant allelic odds ratios, it
is possible to detect mutations conferring resistance using a
few hundred samples typed with 300–500 genetic markers
(Wootton et al. 2002). Of course, for most studies, the scale
of LD in parasite populations is unknown, and many more
markers will have to be used for typing parasite populations
with high recombination rates and for traits that have
unknown history. Fortunately, high-throughput genotyping
methods are now (or soon will be) available; and the num-
ber of genetic markers should no longer be a major concern
for mapping drug-resistant genes.
An intriguing question is how many SNPs that are useful
for genetic mapping can be expected from the
P. falciparum genome? More than 100,000 SNPs have been
deposited in the malaria database PlasmoDB (www.plas-
moDB.org); however, the majority of the SNPs could be
private SNPs (present in a frequency lower than 5% among
parasite isolates) or derived from highly polymorphic anti-
gen gene families (JeVares et al. 2007; Mu et al. 2007;
Volkman et al. 2007). The number of common SNPs that
will be useful for genetic mapping in P. falciparum is likely
to be between 50,000 and 100,000 (Mu et al. 2007), equiva-
lent to the density provided by the estimated 10 million
SNPs in the human genome (Collins et al. 2003). Fortu-
nately, the parasite has a small genome; and even 50,000
SNPs can provide a map with a marker density of one SNP
per 460 bp. Finally, the number of genetic markers required
will depend on the trait being analyzed and many other fac-
tors; we do not want to use too many markers in a study if
we do not have to.
InXuence of a gene on parasite traits
Another factor to consider is how much inXuence a muta-
tion (or allele) exerts on a trait, which is usually unknown
before identiWcation of the mutation. An odds ratio of expo-
sure to the susceptible genetic variant in cases compared
with that in controls greater than 1.5 will also signiWcantly
lower the number of samples required (Wang et al. 2005).
Although most drug-resistance traits are likely to be pheno-
types involving multiple loci, only a limited number of
genes may play a major role in conferring resistance, such
as pfcrt and pfdhfr in CQR and PYR resistance, respec-
tively. Indeed, mutations in these two genes can change
parasite response to CQ and PYR dramatically, converting
a clinically sensitive parasite into a resistant parasite. The
existence of a few genetic loci having large eVects and
numerous loci with small eVects appear to be true for most
phenotypes (Wang et al. 2005). Therefore, the odds ratios
of resistant alleles with resistant phenotypes are likely to be123
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drug-resistant phenotypes in malaria parasites.
Summary
Recent developments in high-throughput genotyping
technologies have made it possible to conduct genome-
wide mapping studies in malaria parasites. For mapping
genes conferring drug-resistance traits, genome-wide
association studies are practical because relatively recent
founder mutations underlie drug resistance, and continued
drug pressure will help preserve LD. For mapping other
phenotypes such as virulence and growth rate diVerences,
much higher densities of genetic markers will be required
due to the complexity of the phenotypes and unknown
evolutionary histories of the mutations. The diYculties in
mapping studies in malaria phenotypes include the collec-
tion of large numbers of parasite samples and accurate
measurement of phenotypic diVerences; however, these
problems can be overcome, and we can expect to see
informative genome-wide association studies in
P. falciparum in the near future. Whether these studies
will help to identify new targets for malaria control
remains to be seen.
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